Fate Therapeutics Files 8-K on Director Changes and Officer Appointments
Ticker: FATE · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-appointment, director-election, filing
Related Tickers: FATE
TL;DR
Fate Therapeutics filed an 8-K: new directors elected, officers appointed, and compensation plans updated.
AI Summary
On June 3, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, the appointment of certain officers, and updates to compensatory arrangements. Additionally, the filing covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate governance changes and potential shifts in executive leadership or compensation structures at Fate Therapeutics.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with updates to compensation, can signal strategic shifts or internal restructuring, which may carry inherent risks.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36076 (identifier) — SEC File Number
- 65-1311552 (identifier) — IRS Employer Identification No.
- 12278 Scripps Summit Dr. (address) — Principal executive offices
- San Diego, CA (location) — Principal executive offices
- 92131 (zip_code) — Principal executive offices
- (858) 875-1800 (phone_number) — Registrant's telephone number
FAQ
What specific changes were made regarding the election of directors?
The filing indicates the election of directors as an item reported, but does not specify the names of newly elected directors or any changes from previous board composition within the provided text.
Were there any new officer appointments announced in this filing?
Yes, the filing lists the 'Appointment of Certain Officers' as an item information, indicating that new officer appointments were made or reported.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is June 3, 2024.
What is the principal executive office address for Fate Therapeutics, Inc.?
The principal executive office address is 12278 Scripps Summit Dr., San Diego, CA 92131.
What is the SIC code for Fate Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Fate Therapeutics, Inc. is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 1,271 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2024-06-07 17:26:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
Filing Documents
- d839723d8k.htm (8-K) — 42KB
- d839723dex101.htm (EX-10.1) — 84KB
- 0001193125-24-157554.txt ( ) — 268KB
- fate-20240603.xsd (EX-101.SCH) — 3KB
- fate-20240603_lab.xml (EX-101.LAB) — 17KB
- fate-20240603_pre.xml (EX-101.PRE) — 11KB
- d839723d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Fate Therapeutics, Inc. Date: June 7, 2024 By: /s/ J. Scott Wolchko Name: J. Scott Wolchko Title: President and Chief Executive Officer